Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Fresh off of speaking at the UN, Amalya Yeghoyan, Executive Director of FAR’s Gyumri Information Technology Center, discusses her work to empower women through tech.
Veetahl Eilat-Raichel, Founder and CEO of Sorbet, shares how employees can harness the value of their time off – and how companies can use PTO to employees’ benefit.
Brooke May, Managing Partner at Evans May Wealth, weighs in on how the market is expected to perform through the rest of 2024, plus why she’s still bullish on tech but cautious when it comes to financials.
Pete Nicoletti, Global CISO at Check Point, explains why it’s so difficult to legislate against A.I. disinformation and why it’s a concern going into the 2024 election.
Michelle Freyre, Clinique Global Brand President, discusses the company's latest ventures and why skin advice should always come from a trusted source.
